Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Net Cash Flow (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Net Cash Flow for 15 consecutive years, with -$844000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 8.07% year-over-year to -$844000.0, compared with a TTM value of -$2.9 million through Sep 2025, up 71.65%, and an annual FY2024 reading of -$5.0 million, up 89.41% over the prior year.
  • Net Cash Flow was -$844000.0 for Q3 2025 at Alaunos Therapeutics, down from -$701000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $15.0 million in Q3 2021 and bottomed at -$23.3 million in Q2 2021.
  • Average Net Cash Flow over 5 years is -$6.1 million, with a median of -$5.9 million recorded in 2023.
  • The sharpest move saw Net Cash Flow surged 182.99% in 2021, then plummeted 570.18% in 2023.
  • Year by year, Net Cash Flow stood at -$15.7 million in 2021, then skyrocketed by 107.98% to $1.3 million in 2022, then tumbled by 570.18% to -$5.9 million in 2023, then soared by 89.94% to -$592000.0 in 2024, then crashed by 42.57% to -$844000.0 in 2025.
  • Business Quant data shows Net Cash Flow for TCRT at -$844000.0 in Q3 2025, -$701000.0 in Q2 2025, and -$772000.0 in Q1 2025.